Let's hope it's big enough news that doing a CC during market hours may require a halt... rather than that, have the call after hours??

On another note, has this U.S. News & World Report article out at noon yesterday been posted here... not sure I've seen it... while we know the story and it's about another drug, it mentions Leronlimab and CytoDyn :

https://www.usnews.com/news/health-news/artic...tudy-finds

Quote:

---

Already, combinations of remdesivir and other drugs are being tried, to see if dual-drug treatments might boost outcomes even more. For example, one federally funded clinical trial is combing remdesivir with a potent anti-inflammatory drug called baricitinib, while a trial from biotech firm CytoDyn is pairing it with an antiviral called leronlimab.

---

I maintain, the PR out Friday evening pretty much told us what the CC will be about... although we may get a surprise or two:

https://investorshangout.com/post/view?id=5776391